Pay in 4 interest-free payments of $7.09 Learn more
Ships within 48 hours · Estimated delivery Sep 3 - Sep 8
Published Phase 2 data shows: Dose Group Discontinuation Due to AE Placebo 0% 1 mg 2.9% 4 mg (escalated) 5.7% 8 mg (escalated) 5.0% 12 mg (escalated) 8.3% For context, discontinuation rates in semaglutide 2.4 mg trials (STEP program) were approximately 7%, and tirzepatide 15 mg trials (SURMOUNT) reported approximately 6-7%
Each injection is administered by licensed clinicians in our clinics
Compounded medications are considered investigational and are explicitly excluded in UnitedHealthcare's medical policy on GLP-1 receptor agonists (policy number 2024T0598H, updated January 2026)
The same protocol applied to an acute tendon injury and a chronic joint pain case will produce two very different timelines
Glucagon Receptor The third receptor activated by Retatrutide, unique among current obesity medications
For researchers transitioning from other compounds, the retatrutide dosage schedule after tirzepatide and switching protocols provide guidance on cross-compound transitions based on available research data
US$ 26.19
US$ 27.31
US$ 28.34
US$ 21.13
US$ 28.83
US$ 23.15
US$ 25.37
US$ 24.19
US$ 26.75
US$ 20.19
